

MEMORANDUM #65

TO: UNC Hospitals, Attending Physicians, Housestaff, Nursing Coordinators, Department Heads and Supervisors

FROM: *JJS* John Schmitz, Ph.D., Director, Flow Cytometry Laboratory, McLendon Laboratories
EW Eric Weimer, Ph.D., Associate Director, Flow Cytometry Laboratory, McLendon Laboratories
MM Marian Rollins-Raval, M.D., Associate Director, Flow Cytometry Laboratory, Laboratories
HCW Herbert C. Whinna, M.D., Ph.D., Medical Director, McLendon Clinical Laboratories

DATE: March 15, 2016

SUBJECT: Flow Cytometric Evaluation of Patients Receiving Cell Depleting Therapies

Recent regulatory activities within the FDA and CMS, related to laboratory developed tests and quality control requirements, have prompted a review of current flow cytometric tests for patients receiving cell depleting therapies such as Thymoglobulin and Rituximab. In response to these regulatory activities, the flow cytometry laboratory will implement revised antibody combinations for the two existing tests. The following table lists the current and revised components of these panels.

Test Name	Test ID	Current Antibody Components	New components
Rituxin/CD20 Workup	RTX20	CD3,CD5,CD16+56, CD19, CD20	CD3, CD16+56, CD19
CD3 Transplant Workup	CD3TX	CD2, CD3, CD4, CD8, CD19	CD3, CD4, CD8

Please note that test names and test codes are not changing.

Please direct any questions to the flow cytometry laboratory at 984-974-1765 or Dr. John Schmitz at 984-974-1452.